Blend 3Q 2026: Revenue $32.91M, EPS ($0.03) — 10-Q Summary

Blend Labs reported 3Q 2026 revenue of $32.91M, up 1% YoY, and a net loss of $0.03 per share. Mortgage Suite revenue fell 2%, while Consumer Banking Suite revenue rose 5%. Gross margin declined to 72% from 74%, and operating expenses decreased 11%.

Original reporting
Published Nov 5, 2026, 9:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 9:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Blend 3Q 2026: Revenue $32.91M, EPS ($0.03) — 10-Q Summary — source image
Decision brief

The 30-second read

$BLNDBearishLow
01

Why it matters

The earnings miss may trigger short‑term sell pressure, but cost reductions could support a longer‑term turnaround narrative.

02

Market read

The filing provides fresh earnings data for a micro‑cap fintech, offering limited but actionable insight for traders focused on small‑cap earnings.

03

What to watch

Operating expense reduction of 11% and G&A cut of 24% could improve future profitability if revenue growth accelerates.

Relevance 6/10Novelty 7/10Timing: after‑hours release

Background

Blend Labs is a fintech company providing mortgage and consumer banking software solutions. The 10‑Q filing details Q3 2026 results.

Company-level read

Ticker impact

$BLNDBearishHigh confidence
Context

Blend Labs reported Q3 2026 revenue of $32.91M and a loss per share of $0.03 in its 10‑Q filing.

Expected impact

downward pressure as the market prices in the loss widening

Evidence & confidence

The filing shows revenue only marginally up while the loss per share increased, a negative earnings surprise for investors.

Market effects

Modest impact on the fintech/consumer‑banking software sector as peers may be compared to Blend's performance.

Limited to U.S. micro‑cap investors; no broader regional effect.

Low global relevance given the company's small size and niche market.

Counterpoint

If the revenue mix shift toward higher‑margin Consumer Banking Suite gains traction, the loss may be temporary.

Key entities

  • Blend Labs, Inc.

    Issuer of the 10‑Q filing.

Related articles

$BLNDMed

Blend Announces Third Quarter 2026 Financial Results

Blend Labs, Inc. (BLND) filed an SEC Form 8-K — Results of Operations and Financial Condition. Blend Announces Third Quarter 2026 Financial Results November 5, 2026 SAN FRANCISCO -- Blend Labs, Inc. (NYSE: BLND), a leading digital banking platform, today announced its third quarter 2026 financial results. “We had our best sales quarter in more than three years,” said Nima

$BLNDMed

Blend Announces Second Quarter 2026 Financial Results

Blend Labs, Inc. (BLND) filed an SEC Form 8-K — Results of Operations and Financial Condition. Blend Announces Second Quarter 2026 Financial Results August 6, 2026 SAN FRANCISCO -- Blend Labs, Inc. (NYSE: BLND), a leading origination platform for digital banking solutions, today announced its second quarter 2026 financial results. "We delivered Q2 with revenue near the hig

$BLNDMed

British Land reports strong Q1 leasing momentum By Investing.com

British Land reported Q1 FY2027 leasing of 567,000 sq ft, completed at 4.8% above estimated rental value and 8.7% above prior passing rents. An extra 1.1m sq ft is under offer. Near-full occupancy was noted for retail parks and London Urban Logistics. Disposals totaled £83m at 3.2% net initial yield. FY2027 underlying EPS guidance of at least 30.5p was kept.

$NETHighAI 8/10

Cloudflare Just Had Its “Best Quarter Ever” on the Day Tech Crashed

Cloudflare (NET) reported strong Q3 2026 earnings, with revenue of $782.5M (+39% YoY) and non-GAAP EPS of $0.38, beating estimates. Despite a 21.2% weekly decline, shares rose 14.72% after-hours. The company raised full-year revenue guidance to $2.963B-$2.964B and expects GAAP profitability in Q4, earlier than previously forecasted. Key metrics like dollar-based net retention (122%) and remaining performance obligations ($2.877B) also improved.

$SANAHighAI 8/10

Sana Biotechnology Reports Q3 Profit; Advances Cell Therapy Programs Toward Clinical Trials

Sana Biotechnology (SANA) reported Q3 2026 net income of $20.4M, with R&D expenses rising to $33.9M. The company has $121.7M in cash, expecting a runway into mid-2027. SANA advanced cell therapy programs for type 1 diabetes and non-Hodgkin lymphoma, targeting clinical trials in 2026-2027. UP421 showed long-term survival in type 1 diabetes study. SANA stock is up 1.75% to $2.38.